A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
P1060 is currently at protocol Version 5.0, which is an extension phase of P1060 Version 4.0. P1060 Version 4.0 was a Phase II,...
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
